%0 Journal Article
%T Severe rebound after cessation of fingolimod treated with ocrelizumab
with coincidental transient aggravation: report of two cases
%A Stephan Schmidt
%A Thomas Schulten
%J Archive of "Therapeutic Advances in Neurological Disorders".
%D 2019
%R 10.1177/1756286419846818
%X Fingolimod (FTY), an oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS), has been associated with a significant rebound of disease activity after cessation of therapy
%K disease-modifying therapy
%K fingolimod
%K multiple sclerosis
%K ocrelizumab
%K rebound
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503590/